Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
Lantus
Description:
A brand-name long-acting insulin glargine medication used to help control blood glucose in people with diabetes.
Primary topic:
Diabetes Management and Research (30%)
Related topics:
Diabetes Management and Research (30%),
Diabetes Treatment and Management (22%),
Biosimilars and Bioanalytical Methods (18%)
Wikidata ID:
wiki/Q417317
OpenAlex ID:
keywords/lantus
Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines
2009
·
Ashish Shukla
, Jean Grisouard
, et al.
·
Endocrine Related Cancer
·
143
PDF
Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies
2015
·
Helle Linnebjerg
, Eric Chen Quin Lam
, et al.
·
Diabetes Care
·
101
Evaluation of the Carcinogenic Potential of Insulin Glargine (LANTUS) in Rats and Mice
2002
·
Ingo Stammberger
, Axel Bube
, et al.
·
International Journal of Toxicology
·
97
Evaluation of the Reproductive Toxicity and Embryotoxicity of Insulin Glargine (LANTUS) in Rats and Rabbits
2002
·
Thomas Hofmann
, Georg Horstmann
, et al.
·
International Journal of Toxicology
·
82
Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review
2018
·
Carolyn Tieu
, Eleanor J. Lucas
, et al.
·
PLoS ONE
·
46
PDF
Mass spectrometric immunoassay of intact insulin and related variants for population proteomics studies
2011
·
Paul E. Oran
, Jason W. Jarvis
, et al.
·
PROTEOMICS - CLINICAL APPLICATIONS
·
43
Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
2016
·
Helle Linnebjerg
, Eric Chen Quin Lam
, et al.
·
Diabetes Obesity and Metabolism
·
33
PDF
Assessment of Commercial and Mandatory Discounts in the Gross-to-Net Bubble for the Top Insulin Products From 2012 to 2019
2023
·
Sean R. Dickson
, Nico Gabriel
, et al.
·
JAMA Network Open
·
28
PDF
Real-World Budget Impact of the Adoption of Insulin Glargine Biosimilars in Primary Care in England (2015–2018)
2020
·
Ion Agirrezabal
, Eduardo Sánchez-Iriso
, et al.
·
Diabetes Care
·
26
Discrete, Chiral Polymer–Insulin Conjugates
2022
·
Wencong Wang
, Yivan Jiang
, et al.
·
Journal of the American Chemical Society
·
24
PDF
The quaternary structure of insulin glargine and glulisine under formulation conditions
2019
·
Norbert Nagel
, Melissa A. Graewert
, et al.
·
Biophysical Chemistry
·
22
Dosing of insulin glargine in the treatment of type 2 diabetes
2007
·
Anthony Barnett
·
Clinical Therapeutics
·
22
Towards in vitro in vivo correlation for modified release subcutaneously administered insulins
2020
·
Frederik Bock
, Eva Lin
, et al.
·
European Journal of Pharmaceutical Sciences
·
21
Basalog® is similar to Lantus® in producing glycemic control in patients with type 1 diabetes mellitus on multiple daily insulin regimens
2011
·
M. Verma
, P. Hazra
, et al.
·
International Journal of Diabetes in Developing Countries
·
21
Comparative evaluation of pharmacokinetics and pharmacodynamics of insulin glargine (Glaritus®) and Lantus® in healthy subjects: a double-blind, randomized clamp study
2018
·
Ashima Bhatia
, Shraddha Tawade
, et al.
·
Acta Diabetologica
·
20
Single‐dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK ‐1293 insulin glargine and originator insulin glargine ( L antus) in subjects with type 1 diabetes and healthy subjects
2017
·
Michael F. Crutchlow
, John S. Palcza
, et al.
·
Diabetes Obesity and Metabolism
·
19
PDF
Dose Accuracy and Injection Force of Different Insulin Glargine Pens
2013
·
Arnd Friedrichs
, Janine Bohnet
, et al.
·
Journal of Diabetes Science and Technology
·
19
LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels
2017
·
Xin Zhang
, Eric Chen Quin Lam
, et al.
·
Clinical Pharmacology in Drug Development
·
17
Safety and efficacy of GP40061 compared with originator insulin glargine (Lantus ® ): a randomized open-label clinical trial
2020
·
Tatiana L Karonova
, Anna A Mosikian
, et al.
·
Journal of Comparative Effectiveness Research
·
13
Real-World Impact of Switching From Insulin Glargine (Lantus®) to Basaglar® and Potential Cost Saving in a Large Public Healthcare System in Saudi Arabia
2022
·
Yazed AlRuthia
, Ohud H. Bahari
, et al.
·
Frontiers in Public Health
·
12
PDF
Further experimentation of inhaled; Lantus, Actrapid and Humulin with todays’ production systems
2013
·
Paul Zarogoulidis
, Dimitris Petridis
, et al.
·
International Journal of Pharmaceutics
·
12
Starting insulin in type 2 diabetes: Overcoming barriers to insulin therapy
2008
·
UdayaM Kabadi
·
International Journal of Diabetes in Developing Countries
·
11
PDF
Studies of pharmacokinetic,pharmacodynamic properties and bioequivalence of recombinant insulin glargine injection in healthy man
2010
·
Pan Chang-yu
·
Zhongguo tangniaobing zazhi
·
10
Real-World Evaluation of Dosing in Patients Converted From Insulin Glargine (Lantus) to Insulin Glargine (Basaglar)
2020
·
Jamie M. Pitlick
, Ginelle A. Bryant
, et al.
·
Annals of Pharmacotherapy
·
9
Pdb21 a Cost-utility Analysis of Insulin Glargine (lantus®) in the Treatment of Patients With Type 1 Diabetes
2003
·
FK Kristensen
, JM Sverre
, et al.
·
Value in Health
·
8
PDF
Show more works
View as search
Works count:
276
Citation count:
1,094
Year
Topic
Type